Recurrent Endometrial Carcinoma Completed Phase 1 Trials for DB11870 (RG-4733)

IndicationStatusPhase
DBCOND0028796 (Recurrent Endometrial Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01198184Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsTreatment